The product ECHO-7 RIGVIR, licensed by the Rigvir group, has become available for public sale online for scientific and industrial purposes. Congratulations to our Estonian partners AramaPharm, and we wish them success in their work.
Interested parties are welcome: www.echo7rigvir.com
The product ECHO-7 RIGVIR, licensed by the Rigvir group, has become available for public sale online for scientific and industrial purposes. Congratulations to our Estonian partners AramaPharm, and we wish them success in their work.
Interested parties are welcome: www.echo7rigvir.com
Rigvir Group has concluded an exclusive license agreement with an Estonia-based company AramaPharm Ltd for the manufacturing and use of the virus Rigvir in the science and industry segment.
Rigvir Group has concluded an exclusive license agreement with an Estonia-based company Aramapharm Ltd for the manufacturing and use of the virus Rigvir in the science and industry segment.
Rigvir virus celebrates its 20th anniversary since it was registered as a medicine. It happened in 2004 in Latvia, and Rigvir became the first virus in the world to go through all preclinical and clinical trial phases, proving high effectiveness and safety.
Read MoreRigvir virus celebrates its 20th anniversary since it was registered as a medicine. It happened in 2004 in Latvia, and Rigvir became the first virus in the world to go through all preclinical and clinical trial phases, proving high effectiveness and safety.
100 years ago, on March 23, 1924, the inventor of Rigvir and the founder of Rigvir group, Aina Muceniece, was born.
Aina Muceniece passed away in 2010, but her initiated work is continued by her educated colleagues and her family, now in the fourth generation. With Muceniece's blessing, the Rigvir virus continues to live on and help many sufferers around the world. Thank you, dear Aina, with love from Rigvir group and your family.
100 years ago, on March 23, 1924, the inventor of Rigvir and the founder of Rigvir group, Aina Muceniece, was born. Aina Muceniece passed away in 2010, but her initiated work is continued by her educated colleagues and her family, now in the fourth generation. With Muceniece's blessing, the Rigvir virus continues to live on and help many sufferers around the world. Thank you, dear Aina, with love from Rigvir group and your family.
Company Smart Nanovirus Limited that has received a licence to develop the Rigvir virus in the non-medicine sector has successfully launched Rigvir SE on the market.
Rigvir Group wishes success and rapid expansion of the good virus around the world.
More information on www.smartnanovirus.com
Company Smart Nanovirus Limited that has received a licence to develop the Rigvir virus in the non-medicine sector has successfully launched Rigvir SE on the market.
More information on www.smartnanovirus.com
Rigvir has once again received international confirmation that it is non-toxic, has high tolerability and does not induce any severe adverse event even at increased doses.
A new publication on the safety and high tolerability of the oncolytic virus Rigvir.
Rigvir has once again received international confirmation that it is non-toxic, has high tolerability and does not induce any severe adverse event even at increased doses.
Rigvir Group has signed a licence agreement with a UK-based company Smart Nanovirus Limited on a fundamentally new approach to cancer prevention, that would allow to identify high cancer risks timely and address them effectively, using the oncolytic virus Rigvir.
Henceforth, Rigvir virus is going to be developed also in the non-medical field which could
provide preventive help to people with high cancer-risks or scientifically proven cancer
presence in the body even before cancer can be diagnosed.
Rigvir group has made a decision to offer a fundamentally new approach to cancer prevention.
Rigvir group has signed a license agreement on the manufacturing, registration, and sales of Rigvir medicine in the CIS (Commonwealth of Independent States) region countries. The license agreement also includes the transfer of marketing authorisation in the CIS countries. With this deal, the Rigvir group has further distanced itself from the commercialisation of the medicine and approached Biotech format with a focus on product development and further licensing.
Read More
We invest in biomanufacturing and we focus on growing our portfolio of virotherapy medicines that meet the real needs of patients.
Products
4-Week repeated dose rat GLP toxicity study of oncolytic ECHO-7
virus Rigvir
The results show that there were no significant test item-related adverse events.
Based on the results, the no-observed-adverse-effect level
(NOAEL) was considered to be the highest dose tested.
The aims of the project have been reached, and as a result a NOAEL (no adverse effect level) has been determined.
Read More
Rigvir's new API (Active pharmaceutical ingredient) center of manufacturing has received GMP (Good Manufacturing Practice) compliance certification for the production of Rigvir virus ECHO-7.
Read More
Numerous viruses have been tested in clinical trials and three are approved. Our virus was the first.
Full Publication
We are committed to prove, that the cancer treatment can be safe, effective and harmless.
Our Company
In the 1960s with the efforts of professor Aina Muceniece the focus points in the perception of cancer started to shift.
Our History
Innovations in biotechnological cancer treatments are the key concepts for improving the health quality of global population.
Focus AreasAccess the latest information regarding our company, people, science, partnerships and opportunities.
ExploreContact us to receive a consultation and/or information about oncolytic virotherapy with ECHO-7 medicine.
Contact Us
